Ascendis Pharma A/S stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Ascendis Pharma A/S stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Ascendis Pharma A/S do? Business model and key facts
Get the full picture of Ascendis Pharma A/S: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 1017
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Stocks related to Ascendis Pharma A/S
Selected based on industry alignment and relative market positioning.
Events and news impacting Ascendis Pharma A/S stock
Earnings, coporate decisions and industry developments that can affect the share price.
Ascendis Pharma A/S fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
